Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1111/j.1582-4934.2010.01108.x

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:15035037

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Erratum

Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway

Jun Cai a, b, Fang-Fang Yi b, Zhou-Yan Bian c, d, Di-Fei Shen c, d, Long Yang b, Ling Yan c, d, Qi-Zhu Tang c, d, Xin-Chun Yang b, Hongliang Li c, d

a Cardiovascular Research Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA
b Department of Cardiology, Beijing Chaoyang Hospital, Affiliate of Capital Medical University, Beijing, China
c Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
d Cardiovascular Research Institute of Wuhan University, Wuhan, China

There is a correction concerning the correspondence details of an article published in a previous issue of the Journal of Cellular and Molecular Medicine [1]. The correspondence (*) symbol was attributed to both X-C Yang and H Li’s names in the authors list. However, corresponding details were only presented for X-C Chang. H Li’s corresponding details are as follows:

Hongliang Li, M.D., Ph.D.,
Cardiovascular Research Institute of Wuhan University,
JieFang Road 238, Wuhan 430060, China.
Tel./Fax: (86)-27-88083385
E-mail: hongliang.li@ymail.com

We apologise for this error.